Literature DB >> 19418607

Hepatocellular carcinoma in patients with cryptogenic cirrhosis.

Edoardo Giovanni Giannini1, Elisa Marabotto, Vincenzo Savarino, Franco Trevisani, Maria Anna di Nolfo, Paolo Del Poggio, Luisa Benvegnù, Fabio Farinati, Marco Zoli, Franco Borzio, Eugenio Caturelli, Maria Chiaramonte.   

Abstract

BACKGROUND & AIMS: Patients with cryptogenic cirrhosis (CC) can develop hepatocellular carcinoma (HCC), although the clinical characteristics of HCC in these patients have not been completely defined. We aimed to characterize the clinical features of patients diagnosed with HCC after CC during a 15-year period (1992-2006).
METHODS: The clinical characteristics of 45 consecutive CC patients with HCC were analyzed, along with modality of diagnosis, tumor stage, treatment, survival, and causes of death. Data were compared with those of 426 consecutive patients with HCC and only hepatitis C virus (HCV) infection, diagnosed during the same period at the Italian Liver Cancer group centers.
RESULTS: HCC patients with CC had similar impairments in liver function as patients with HCV infection (Child-Pugh class A: 53% vs 65%; P = .141). However, the HCC patients with CC had lower aminotransferase levels (P < .001) and higher platelet counts (P < .001). HCC was significantly less likely to be diagnosed during surveillance in CC patients (29% vs 64%; P < .0001). Patients with CC had a significantly greater prevalence of advanced HCC stage, according to Milano criteria (69% vs 41%; P < .0005), larger HCC size (4.9 vs 3.0 cm; P = .0001), lower amenability to any treatment (27% vs 42%; P = .036), and shorter survival times (P = .009, log-rank test) compared with HCV patients. Causes of death were similar in the 2 groups.
CONCLUSIONS: Compared with HCV patients, HCC in CC patients often is diagnosed at an advanced stage, probably owing to lack of surveillance; this leads to limited treatment options and shorter survival times.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19418607     DOI: 10.1016/j.cgh.2009.01.001

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  17 in total

Review 1.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review.

Authors:  Yoshitaka Takuma; Kazuhiro Nouso
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

Review 2.  Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Authors:  Pegah Golabi; Logan Rhea; Linda Henry; Zobair M Younossi
Journal:  Hepatol Int       Date:  2019-11-07       Impact factor: 6.047

3.  Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population.

Authors:  Sahil Mittal; Yvonne H Sada; Hashem B El-Serag; Fasiha Kanwal; Zhigang Duan; Sarah Temple; Sarah B May; Jennifer R Kramer; Peter A Richardson; Jessica A Davila
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-19       Impact factor: 11.382

Review 4.  Cryptogenic chronic hepatitis and its changing guise in adults.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-06-07       Impact factor: 3.199

Review 5.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

6.  Comparison of Hepatocellular Carcinoma in Patients with Cryptogenic Versus Hepatitis B Etiology: A Study of 1079 Cases Over 3 Decades.

Authors:  Zhong-Hong Liew; George Boon-Bee Goh; Ying Hao; Pik-Eu Chang; Chee-Kiat Tan
Journal:  Dig Dis Sci       Date:  2018-10-16       Impact factor: 3.199

Review 7.  HCV drug discovery aimed at viral eradication.

Authors:  R F Schinazi; L Bassit; C Gavegnano
Journal:  J Viral Hepat       Date:  2009-12-18       Impact factor: 3.728

Review 8.  Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it?

Authors:  Edoardo G Giannini; Alessandro Cucchetti; Virginia Erroi; Francesca Garuti; Federica Odaldi; Franco Trevisani
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

Review 9.  Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight.

Authors:  Stefano Ballestri; Fabio Nascimbeni; Dante Romagnoli; Enrica Baldelli; Giovanni Targher; Amedeo Lonardo
Journal:  Int J Mol Sci       Date:  2016-03-09       Impact factor: 5.923

10.  Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience.

Authors:  Brian Shrager; Ghalib A Jibara; Parissa Tabrizian; Sasan Roayaie; Stephen C Ward
Journal:  Int J Surg Oncol       Date:  2012-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.